AppTec

WuXi AppTec to Launch a Special Webinar on Collaborations that Transform on July 16 | Advances in Rare Diseases: Hemophilia

Retrieved on: 
Thursday, July 9, 2020
Branches of biology, Life sciences, Biology, WuXi AppTec, Biotechnology, AppTec, Gene therapy, Wuxi

SHANGHAI and SAN DIEGO, July 9, 2020 /PRNewswire/ -- WuXi AppTec is pleased to announcethat they are about to launch the second session ofthe webinar series "Collaborations That Transform," highlighting the impact of partnerships in bringing effective therapies to patients.

Key Points: 
  • SHANGHAI and SAN DIEGO, July 9, 2020 /PRNewswire/ -- WuXi AppTec is pleased to announcethat they are about to launch the second session ofthe webinar series "Collaborations That Transform," highlighting the impact of partnerships in bringing effective therapies to patients.
  • This complimentary webinar, to be broadcast worldwide on July 16, will convene leading physicians, drug developers, patients and advocates.
  • These experts will discuss the latest advances in the development of transformative medicines for hemophilia, including gene therapy and next generation technologies.
  • WuXi AppTec welcomes all to join the conversation.

WuXi AppTec Appoints Dr. David Chang as CEO of WuXi Advanced Therapies Business Unit

Retrieved on: 
Monday, June 1, 2020
Life sciences, Articles, Health sciences, WuXi AppTec, Biotechnology, Pharmaceutical industry, AppTec, Therapy, Biopharmaceutical

Dr. Chang brings strong leadership and a wealth of experience in cell and gene therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy.

Key Points: 
  • Dr. Chang brings strong leadership and a wealth of experience in cell and gene therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy.
  • "We are delighted to welcome Dr. Chang as CEO of WuXi ATU to lead our cell and gene therapy CDMO business to the next stage of growth," said Mr. Edward Hu, Vice Chairman and Global Chief Investment Officer of WuXi AppTec.
  • "I'm very honored to join WuXi AppTec," said Dr. Chang.
  • As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

WuXi Advanced Therapies Launches New World-Class AAV Vector Suspension Platform

Retrieved on: 
Monday, January 13, 2020
WuXi AppTec, Pharmaceutical industry, Life sciences, Contract manufacturing organization, Adeno-associated virus, AppTec, Wuxi, Articles, Industries, WuXi Biologics

PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.

Key Points: 
  • PHILADELPHIA, Jan. 13, 2020 /PRNewswire/ -- WuXi Advanced Therapies, a leading global Contract Development and Manufacturing Organization (CDMO) offering end-to-end contract services for the advance therapies industry, announced today the expansion of its service capabilities by offering a fully integrated adeno-associated virus (AAV) Vector Suspension Platform to help accelerate the timeline for cell and gene therapy development, manufacturing and release while providing greater predictability.
  • "We are excited to bring a world-class AAV Suspension Platform to our customers," said Felix Hsu, Senior Vice President and Global Head of WuXi AppTec Advanced Therapies.
  • "We will continue to develop platforms that help our customers bring their innovative therapies to patients and to market with even greater predictability and speed."
  • As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

WuXi AppTec Receives 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan

Retrieved on: 
Friday, November 15, 2019
WuXi AppTec, AppTec, Wuxi, Life sciences, Industries, Companies

SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm.

Key Points: 
  • SHANGHAI, Nov. 14, 2019 /PRNewswire/ -- WuXi AppTec, a leading global provider of R&D and manufacturing services enabling companies in the pharmaceutical, biotechnology and medical device industries, today announced that it received the 2019 Global Integrated Drug Development Competitive Strategy Innovation & Leadership Award from Frost & Sullivan, a global business research and consulting firm.
  • The Frost & Sullivan Best Practices Award series honors companies that have pushed the boundaries of excellence in the areas of leadership, technological innovation, customer service, and business development.
  • Frost & Sullivan recognized WuXi AppTec as a reliable and reputable participant in the global healthcare industry, providing cutting-edge drug discovery and development solutions alongside data management and analytics services.
  • "Thanks Frost & Sullivan for recognizing WuXi's global platform," said Dr. Ge Li, chairman and CEO of WuXi AppTec.

Dr. Ge Li Awarded "CEO of the Year" at CPhI Worldwide 2019

Retrieved on: 
Monday, November 11, 2019
Companies, Industries, WuXi AppTec, Articles, General Electric, Pharma, Wuxi, AppTec, Credibility

The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward.

Key Points: 
  • The 2019 CPhI Pharma Awards recognize the innovation and dedication of companies and individuals who are driving the pharmaceutical industry forward.
  • Its Judging Panel is comprised of independent, senior industry experts from around the world, each chosen for their knowledge, objectivity and credibility.
  • Dr. Ge Li was chosen for his significant contribution to the global biopharma R&D industry.
  • "I'm honored by this award and its recognition of WuXi's global platform," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.

WuXi AppTec Receives Investment Grade Corporate Ratings from Three Global Rating Agencies

Retrieved on: 
Wednesday, November 6, 2019
Finance, Money, Economy, Credit rating agencies, WuXi AppTec, Credit rating, AppTec, Standard & Poor's, Bond credit rating, Moody's Investors Service, Fitch Ratings

SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec.

Key Points: 
  • SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- WuXi AppTec announced today that it has received investment grade corporate credit ratings from three global rating agencies: Moody's (Baa3), S&P Global Ratings (BBB-), and Fitch Ratings (BBB-); all three agencies maintain a stable outlook on WuXi AppTec.
  • These ratings reflect WuXi AppTec's leading market position as an integrated end-to-end R&D service platform with strong growth prospects, healthy cash flow and balance sheet, modest leverage and ample liquidity.
  • Third-party recognition of WuXi AppTec's financial stability enables the Company to also fund future growth with debt.
  • As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient solutions.

WuXi AppTec Named One of MIT Technology Review's 50 Smartest Companies

Retrieved on: 
Saturday, June 29, 2019
Companies, Industries, WuXi AppTec, AppTec, MIT Technology Review, Wuxi, General Electric

SHANGHAI, June 29, 2019 /PRNewswire/ --WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019.

Key Points: 
  • SHANGHAI, June 29, 2019 /PRNewswire/ --WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, announces that it has been selected as one of MIT Technology Review's 50 Smartest Companies (TR50) for 2019.
  • MIT Technology Reviewis one of the world's preeminent technology publication and has been publishing this prestigious accolade since 2010.
  • The 50 Smartest list was created to recognize companies that "best combine innovative technology with an effective business model."
  • "It is our honor to be recognized by MIT Technology Review," said Dr. Ge Li, Chairman and CEO of WuXi AppTec.

Altasciences and WuXi AppTec Enter Into Collaboration for WIND Projects

Retrieved on: 
Thursday, May 16, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Professional services, Consulting, WuXi AppTec, Articles, Life sciences, AppTec, Industries, Contract research organization

WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.

Key Points: 
  • WuXi Clinical, the clinical CRO arm of WuXi AppTec, will be responsible for managing the partnership and ensuring a seamless experience.
  • WuXi AppTec and Altasciences share the same vision, which is to provide a seamless, integrated transition from one key milestone to the next during the early phases of drug development.
  • For over 25 years, Altasciences has been integrating intoclients projects to help support educated, faster, and more complete early drug development decisions.
  • WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform company with global operations.

WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer

Retrieved on: 
Monday, April 8, 2019
WuXi AppTec, AppTec, Wuxi, Life sciences, Industries, East China, Draft:WuXi Biologics

SHANGHAI and AUSTIN, Texas, April 7, 2019 /PRNewswire/ --WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.

Key Points: 
  • SHANGHAI and AUSTIN, Texas, April 7, 2019 /PRNewswire/ --WuXi AppTec, a leading global pharmaceutical and medical device open-access capability and technology platform company, today announces the appointment of Dr. Frederick H. Hausheer as Chief Medical Officer for the company.
  • In this executive role, Dr. Hausheer will provide medical, scientific and operational leadership to WuXi Clinical operations in the United States, China and other territories.
  • "We're very excited to welcome Dr. Hausheer onboard as our Chief Medical Officer," said Mr. Edward Hu, Co-CEO of WuXi AppTec.
  • WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations.

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services

Retrieved on: 
Monday, December 10, 2018
WuXi AppTec, Pharmaceutical industry, AppTec, Contract manufacturing organization, Wuxi, Biotechnology, Economy of China, Health, Draft:WuXi Biologics, Pharmaceuticals policy

The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries.

Key Points: 
  • The expansion will provide key elements of WuXi's small molecule capability and technology platform under one roof, further enhancing services to North American pharmaceutical and biotech industries.
  • WuXi AppTec is a global capability and technology platform company with 27 sites around the world.
  • WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations.
  • STA Pharmaceutical, a subsidiary of WuXi AppTec (WuXi STA), is a premier Contract Development and Manufacturing Organization (CDMO) with operations here in San Diego and China, offering our worldwide partners integrated "end-to-end" supply chain solutions for small molecule Active Pharmaceutical Ingredients (APIs) and finished dosage forms.